Compare XBIO & GDC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | XBIO | GDC |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | 5 |
| Industry | Biotechnology: Pharmaceutical Preparations | Steel/Iron Ore |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.9M | 6.5M |
| IPO Year | 2011 | N/A |
| Metric | XBIO | GDC |
|---|---|---|
| Price | $2.40 | $1.45 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 93.6K | ★ 1.2M |
| Earning Date | 05-13-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 38.52 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $2,976,411.00 | N/A |
| Revenue This Year | $2.81 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $7.47 |
| Revenue Growth | ★ 19.04 | N/A |
| 52 Week Low | $1.90 | $0.01 |
| 52 Week High | $13.93 | $8.18 |
| Indicator | XBIO | GDC |
|---|---|---|
| Relative Strength Index (RSI) | 38.27 | 50.78 |
| Support Level | $2.09 | $1.32 |
| Resistance Level | $2.95 | $2.07 |
| Average True Range (ATR) | 0.36 | 0.18 |
| MACD | -0.19 | 0.02 |
| Stochastic Oscillator | 14.89 | 28.55 |
Xenetic Biosciences Inc is a biopharmaceutical company focused on advancing immuno-oncology technologies addressing difficult-to-treat cancers. The company's DNase technology is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in the progression of many human cancers. Xenetic is also focused on advancing its systemic DNase program into the clinic as an adjunctive therapy for pancreatic carcinoma and other locally metastatic solid tumors. Its product pipeline consists of two key programs, XBIO-015 and XBIO-020, which are being developed to address pancreatic carcinoma and solid tumours.
GD Culture Group Ltd operates and manages its business as a single segment and has one operating and reportable segment, the Virtual Content Production. The company has relentlessly been focusing on serving its customers and creating value for them through the continual innovation and optimization of its products and services. For the AI-driven digital human creation and customization sector, the Company uses AI algorithms and software to generate realistic 3D or 2D digital human models. AI algorithms and machine learning models are used to simulate human characteristics, such as facial expressions, body movements, and even speech patterns.